Search clinical trials for: E6011

Total 9 results

EA Pharma Co., Ltd.

Completed

A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease

Crohn's Disease

Japan
Eisai Co., Ltd.

Completed

A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Biologics

Rheumatoid Arthritis

Japan
Eisai Co., Ltd.

Completed

A Dose Response Study of E6011 in Participants With Rheumatoid Arthritis Inadequately Responding to Methotrexate

Rheumatoid Arthritis

Japan
EA Pharma Co., Ltd.

Terminated

Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid

Primary Biliary Cholangitis

Japan
Eisai Inc.

Withdrawn

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease

Crohn's Disease
Eisai Co., Ltd.

Completed

A Phase 1 Single Dose Study of E6011 in Japanese Healthy Adult Male Subjects (Study E6011-J081-001)

Healthy Male Volunteers

Japan
EA Pharma Co., Ltd.

Active, not recruiting

A Study of E6011 in Participants With Active Crohn's Disease

Crohn's Disease

Czechia, Hungary, Japan, Poland, Russian Federation
Eisai Co., Ltd.

Completed

A Study of E6011 in Japanese Subjects With Rheumatoid Arthritis

Arthritis, Rheumatoid

Japan
Eisai Co., Ltd.

Completed

A Phase 1 Study of Single-dose Subcutaneous E6011 in Japanese Healthy Adult Male Subjects

Healthy

Japan

3

Subscribe